Clinical Trial Update: Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating neoadjuvant chemoradiation with or without bevacizumab for locally advanced esophageal squamous cell carcinoma (Stage III).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Stage III Esophageal Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN